Costs associated with diffuse large B-cell lymphoma patient treatment in a Canadian integrated cancer care center

Value in Health

Volumn 11, Issue 2, 2008, Pages 221-230

  Lee, Robert C ^a,b,c,g   Zou, Denise ^a   Demetrick, Douglas J ^a,d   DiFrancesco, Lisa M ^a,d   Fassbender, Konrad ^e   Stewart, Douglas ^a,f  

^a UNIVERSITY OF CALGARY   (Canada)

^b Calgary Health Technology Implementation Unit   (Canada)

^c INSTITUTE OF HEALTH ECONOMICS   (Canada)

^d CALGARY LABORATORY SERVICES   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

^f TOM BAKER CANCER CENTRE   (Canada)

^g UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; CHOP; Drug combinations; Economics; Health care costs; Microcosting; Neoplasms; R CHOP

Indexed keywords

ARABINOSIDE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOSINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; HYDROCORTISONE; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; THIOTEPA; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANADA; CANCER RADIOTHERAPY; CANCER STAGING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG COST; HEALTH CARE COST; HOSPITAL COST; HOSPITALIZATION; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MEDICAL RECORD; MULTIPLE CYCLE TREATMENT; ONCOLOGY WARD; PALLIATIVE THERAPY; PRIORITY JOURNAL;

EID: 41549099176     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00227.x     Document Type: Article

References (20)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998 16 : 2780 95.
2. World Health Organization. Classification of Tumours: Pathology and Genetics, Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France : IARC Press, 2001.
3. Copson E. Non-Hodgkin's lymphoma (diffuse large B cell lymphoma). Clin Evid 2006 15 : 30 44.
4. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002 346 : 235 42.
5. Haberman T, Weller E, Morrison V, et al. Rituximab-CHOP versus CHOP with or without maintenance rituximab in patietns 60 years of age and older with diffuse large B cell lymphoma (DLBCL): an update. Blood 2004 104 (Abstract 127).
6. Pfreundschuh MG, Trumper L, Ma D, et al. Randomized intergroup trial of first-line treatment for patients ≤60 years with diffuse large B-cell non-Hodgkin's lymphoma with a CHOP-like regimen with or without the anti-CD20 antibody rituximab - early stopping after the first interim analysis. Proc ASCO 2004 556a.
7. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005 23 : 5027 33.
8. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005 23 : 4117 26.
9. Knight C, Hind D, Brewer N, Abbott V. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation. Health Technol Assess 2004 8 : 1 82.
10. Groot MT, Lugtenburg PJ, Hornberger J, et al. Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands. Eur J Haematol 2005 74 : 194 202.
11. Hornberger JC, Best JH. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer 2005 103 : 1644 51.
12. Best JH, Hornberger J, Proctor SJ, et al. Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma. Value Health 2005 8 : 462 70.
13. van Agthoven M, Faber LM, Uyl-de Groot CA, et al. Cost analysis of CHOP (-like) chemotherapy regimens for patients with newly diagnosed aggressive non-Hodgkin's lymphoma. Eur J Haematol 2002 69 : 213 20.
14. van Agthoven M, Vellenga E, Fibbe WE, et al. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease. A prospective randomized trial. Eur J Cancer 2001 37 : 1781 9.
15. van Agthoven M, Sonneveld P, Verdonck LF, Uyl-de Groot CA. Cost determinants in aggressive non-Hodgkin's lymphoma. Haematologica 2005 90 : 661 71.
16. van Agthoven M, Uyl-de Groot CA, Sonneveld P, Hagenbeek A. Economic assessment in the management of non-Hodgkin's lymphoma. Expert Opin Pharmacother 2004 5 : 2529 48.
17. Hunink M, Glasziou P, Siegel J, et al. Decision Making in Health and Medicine. Cambridge : University of Cambridge Press, 2001.
18. Drummond M, McGuire A, eds. Economic Evaluation in Health Care: Merging Theory with Practice. Oxford : Oxford University Press, 2001.
19. Fassbender K, Fainsinger R, Brenneis C, et al. Utilization and costs of the introduction of system-wide palliative care in Alberta, 1993-2000. Palliat Med 2005 19 : 513 20.
20. Fisher L, van Belle G. Biostatistics: A Methodology for the Health Sciences. New York : John Wiley & Sons, 1993.